Publications

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018

Annals of oncology : official journal of the European Society for Medical Oncology

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

08-04-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

07-04-2025

Medical decision making : an international journal of the Society for Medical Decision Making

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

01-04-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

01-04-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Prospective Randomised Phase-II Trial of Ipilimumab/Nivolumab versus Standard of Care in non-clear cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial.

01-04-2025

European journal of cancer (Oxford, England : 1990)

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.

11-03-2025

The oncologist

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

10-03-2025

European journal of cancer (Oxford, England : 1990)

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

07-03-2025

ESMO open

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series.

01-03-2025

Nature medicine

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

01-03-2025

Transplantation and cellular therapy

Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products.

01-03-2025

Journal of the National Cancer Institute

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

21-02-2025

European journal of cancer (Oxford, England : 1990)

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

05-02-2025

European journal of cancer (Oxford, England : 1990)

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

05-02-2025

Nature biotechnology

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

01-02-2025

Journal of cancer survivorship : research and practice

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

01-02-2025

Journal for immunotherapy of cancer

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

20-01-2025

Nature communications

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

14-01-2025

Immunity

Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation.

14-01-2025

The New England journal of medicine

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

02-01-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

01-01-2025

Frontiers in immunology

Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.

24-12-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.

01-12-2024

ESMO open

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

01-12-2024

Gynecologic and obstetric investigation

Assisted Reproductive Technology, Pregnancy, and Recurrent Disease in Melanoma Patients: A 30-Year Single Institution Experience.

15-11-2024

JCI insight

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

08-11-2024

The New England journal of medicine

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

07-11-2024

European journal of cancer (Oxford, England : 1990)

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

01-11-2024

Nature medicine

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

01-11-2024

International journal of cancer

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

15-10-2024

ESMO open

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology.

01-10-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

01-10-2024

Frontiers in immunology

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

11-09-2024

Oncoimmunology

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

27-08-2024

European journal of cancer (Oxford, England : 1990)

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

01-08-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

01-08-2024

Clinical nuclear medicine

Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication.

01-08-2024

JAMA network open

Long-Term Survival in Patients With Advanced Melanoma.

01-08-2024

Cancers

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

26-07-2024

Cancer discovery

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.

01-07-2024

Journal for immunotherapy of cancer

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

30-06-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.

01-06-2024

Cancer medicine

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.

01-06-2024

Scientific reports

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

16-05-2024

International journal of cancer

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

15-05-2024

Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-05-2024

Cancer

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

01-05-2024

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Prospective Randomised Phase-II Trial of Ipilimumab/Nivolumab versus Standard of Care in non-clear cell Renal Cell Cancer - Results of the SUNNIFORECAST Trial.

Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model.

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series.

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products.

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation.

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system.

Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

Assisted Reproductive Technology, Pregnancy, and Recurrent Disease in Melanoma Patients: A 30-Year Single Institution Experience.

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology.

Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication.

Long-Term Survival in Patients With Advanced Melanoma.

Adverse Events in Anti-PD-1-Treated Adjuvant and First-Line Advanced Melanoma Patients.

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.

Treatment patterns and survival outcomes of patients admitted to the intensive care unit due to immune-related adverse events of immune checkpoint inhibitors.

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

A prediction model for response to immune checkpoint inhibition in advanced melanoma.

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.

This site uses cookies